A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
- Conditions
- Interventions
- First Posted Date
- 2024-06-10
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 39
- Registration Number
- NCT06449651
- Locations
- ๐ซ๐ท
CHRU Lille, Lille, France
๐ญ๐บSemmelweis Egyetem, Budapest, Hungary
๐ณ๐ดUniversitetssykehuset Nord-Norge HF, Tromso, Norway
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 100
- Registration Number
- NCT06425991
- Locations
- ๐จ๐ฆ
Cross Cancer Institute, Edmonton, Alberta, Canada
๐ฎ๐ฑCarmel Medical Center, Haifa, Israel
๐ฎ๐ฑHadassah University Hospita Ein Kerem, Jerusalem, Israel
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 217
- Registration Number
- NCT06385080
- Locations
- ๐จ๐ณ
Changhua Christian Hospital, ChangHua, Taiwan
๐จ๐ณChang Kung Memorial Hospital, Kaohsiung City, Taiwan
๐จ๐ณNational Taiwan University Hospital, Taipei, Taiwan
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 540
- Registration Number
- NCT06319820
- Locations
- ๐บ๐ธ
Moffitt Cancer Center, Tampa, Florida, United States
๐ฆ๐นMedizinische Universitaet Graz, Graz, Austria
๐ง๐ทAssociacao Hospitalar Moinhos de Vento, Porto Alegre, Brazil
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2024-02-15
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06260163
- Locations
- ๐ฆ๐บ
The Kids Research Institute Australia on behalf of the Centre for Child Health Research, Nedlands, Australia
๐ฆ๐บThe Children's Hospital at Westmead, Westmead, Australia
๐จ๐ณSir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, China
A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06255665
- Locations
- ๐ช๐ธ
Hosp Univ Fund Jimenez Diaz, Madrid, Spain
๐ช๐ธHosp Univ Vall D Hebron, Barcelona, Spain
๐ช๐ธHosp Univ Hm Sanchinarro, Madrid, Spain
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
- Conditions
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 731
- Registration Number
- NCT06220604
- Locations
- ๐ฉ๐ช
Universitatsmedizin der Johannes Gutenberg Universitat Mainz, Mainz, Germany
๐ต๐ฑWroMedica I Bielicka A Strzalkowska s c, Wroclaw, Poland
๐บ๐ธEssential Medical Research, Tulsa, Oklahoma, United States
A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guรฉrin (BCG)
- Conditions
- Interventions
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 250
- Registration Number
- NCT06211764
- Locations
- ๐บ๐ธ
Low Country Urology Clinics, North Charleston, South Carolina, United States
๐บ๐ธHouston Metro Urology, Houston, Texas, United States
๐บ๐ธThe Urology Group, Cincinnati, Ohio, United States
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 795
- Registration Number
- NCT06208150
- Locations
- ๐จ๐ณ
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
๐จ๐ณTongji Hospital, Tongji Medical College of HUST, Wuhan, China
๐ฎ๐ฑCarmel Medical Center, Haifa, Israel
A Study of Sterile Saline Infusion in Healthy Volunteers
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT06194578
- Locations
- ๐บ๐ธ
Thomas Jefferson University, Philadelphia, Pennsylvania, United States